Loading quotes...

Forecast

The analysts' average price target is €7.60 (-21.57%). The median is €7.15 (-26.21%).

Buy	8
Hold	9
Sell	0

News Go to news feed

Certara misses Q2 forecast; stock falls about 16%

Certara reported adjusted EPS of $0.08 for Q2 on revenue of $93.3 million, missing consensus estimates and sending the stock down about 16% in premarket trading. The software business grew moderately, while the services segment saw declines in revenue and bookings; adjusted EBITDA and margins fell slightly. Management confirmed full-year revenue and EPS targets, narrowed the EBITDA margin guidance to 29–31% and expects margin improvement from cost reductions; a $50 million share buyback program was approved. » More on de.investing.com
Certara: CFO John Gallagher resigns, interim CFO named and annual guidance confirmed

Certara announces the resignation of Chief Financial Officer John Gallagher effective July 14, 2026. Faiz Mohammed will serve as interim CFO; the company has hired an executive search firm to find a permanent successor. Certara leaves its 2026 financial guidance unchanged; the stock had recently risen sharply and analysts still view the shares as potentially undervalued. » More on de.investing.com
Certara reorganizes around ACE and MID3, pushes AI integration and seeks $10M in cost cuts

Certara announced a strategic realignment into two growth engines—ACE (accelerating clinical evidence) and MID3 (model-informed drug development and discovery)—to simplify operations and sharpen go-to-market execution. Management is embedding AI across products and internal functions, developing AI-native modules and a unifying data layer led by a new chief AI officer. The company targets about $10 million in cost reductions while maintaining R&D at roughly 10–11% of sales, and emphasizes scientist-to-scientist sales engagement and organic growth over near-term M&A. » More on finance.yahoo.com

Financials

In the last quarter, CERTARA INC. DL-,01 had revenue of €81.72m and net profit of -€48.43m

(EUR)	June 2026	YoY
Revenue	81.72m	7.88%
Gross profit	50.95m	5.95%
Net profit	-48.43m	2,800.42%
EBITDA	10.41m	58.92%

Fundamentals

Metric	Value
Market capitalization	€1.5bn
Number of shares	152.54m
52-week high/low	€10.62 - €3.98
Dividends	No
Beta	1.43
P/E ratio	-24.85
PEG ratio	0.05
P/B ratio	1.76
P/S ratio	4.12

Company profile

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Name	CERTARA INC. DL-,01
CEO	Jon Resnick
Headquarters	Radnor, pa USA
Website	certara.com
Sector	Health Care
Industry	Health Care Technology
IPO	11/12/2020
Employees	1,546